Sam Brusco, Associate Editor09.12.23
Treace Medical Concepts has begun limited market release in the U.S. of three new complementary technologies to for treatment of bunions and for bunion-related procedures.
The Hammertoe PEEK fixation system, designed to treat hammertoe, claw toe, and mallet toe deformities, is comprised of a sterile-packed implant and instrument kit. Treace said the PEEK implant offers radiolucency and mechanical properties comparable to bone. The company also said the cannulated system can streamline insertion and allow accurate placement of implants.
The LapiTome and RazorTome osteotomies are sterile, single-use instruments designed for more efficient bone slice and soft tissue release and removal in Treace’s Lapiplasty and Adductoplasty procedures. Both expand the company’s current offering of SpeedRelease and TriTome sterile instruments, which were released last year.
“In addition to the large and underpenetrated market for treating bunions, these new technologies are expected to meaningfully expand our addressable market opportunity to include additional procedures that complement our proprietary Lapiplasty and Adductoplasty procedures,” John T. Treace, CEO, founder, and board member of Treace told the press. “We are also looking forward to the upcoming full market launch of our second-generation SpeedPlate fixation platform in the fourth quarter, which will feature a portfolio of compressing anatomic implants, complemented by Micro-Lapiplasty minimally invasive instrumentation. Once fully available, these new product introductions are expected to begin contributing to our growth profile in the fourth quarter with a more meaningful contribution expected in 2024 and beyond.”
The company said full market release is expected in Q4 2023.
The Hammertoe PEEK fixation system, designed to treat hammertoe, claw toe, and mallet toe deformities, is comprised of a sterile-packed implant and instrument kit. Treace said the PEEK implant offers radiolucency and mechanical properties comparable to bone. The company also said the cannulated system can streamline insertion and allow accurate placement of implants.
The LapiTome and RazorTome osteotomies are sterile, single-use instruments designed for more efficient bone slice and soft tissue release and removal in Treace’s Lapiplasty and Adductoplasty procedures. Both expand the company’s current offering of SpeedRelease and TriTome sterile instruments, which were released last year.
“In addition to the large and underpenetrated market for treating bunions, these new technologies are expected to meaningfully expand our addressable market opportunity to include additional procedures that complement our proprietary Lapiplasty and Adductoplasty procedures,” John T. Treace, CEO, founder, and board member of Treace told the press. “We are also looking forward to the upcoming full market launch of our second-generation SpeedPlate fixation platform in the fourth quarter, which will feature a portfolio of compressing anatomic implants, complemented by Micro-Lapiplasty minimally invasive instrumentation. Once fully available, these new product introductions are expected to begin contributing to our growth profile in the fourth quarter with a more meaningful contribution expected in 2024 and beyond.”
The company said full market release is expected in Q4 2023.
